Arndt Vogel/X
Jun 27, 2024, 08:31
Arndt Vogel: Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI
Arndt Vogel shared on X:
“Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI in advanced GI cancers at ESMOGI24
- MINOTAUR study
- Interesting MOA, for 20% of pts w/ CCCN1 amp or mFBXW7 >synthetically lethality
- acceptable safety, “promising” efficacy”
Source: Arndt Vogel/X
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19